Велметия

Quick links

Choose a section

Quick links to important sections

Advertisements

Велметия

Advertisements

Overview of Велметия

Что такое Велметия и ее Фармакологический Класс?

Свойство (Property) Описание (Description)
Активный ингредиент (Active ingredient) Sitagliptin (DPP-4 inhibitor), Metformin (Biguanide)
Форма (Form) Фильмопокрытые таблетки (Film-coated tablets)
Фармакологический класс (Pharmacological class) Антигипергликемическое комбинированное средство (Antihyperglycaemic Combination Agent)
Общее назначение (General purpose) Контроль глюкозы при диабете 2 типа (Glucose control in Type 2 Diabetes)
Происхождение (Origin) Синтетическое (Synthetic)

Велметия is defined as a fixed-dose combination antihyperglycaemic agent used for the management of Type 2 Diabetes Mellitus. This medicine is prescription-only and contains two separate active ingredients in a single film-coated tablet for oral administration. This combination is intended to provide stabilization of blood sugar levels when Metformin monotherapy is insufficient.

This medicine represents a dual combination therapy, incorporating Sitagliptin (specifically Sitagliptin Phosphate Monohydrate) and Metformin Hydrochloride, both synthetic compounds. Sitagliptin belongs to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, while Metformin is categorized as a biguanide. This formulation is distinct from single-component therapies and provides a comprehensive approach to treatment.

Состав: Двойной Подход к Управлению Глюкозой

The primary active ingredients belong to two distinct pharmacological classes. Metformin primarily lowers blood sugar by reducing the liver's glucose output and enhancing the body’s sensitivity to insulin. This dual composition ensures the medicine addresses multiple defects associated with type 2 diabetes concurrently.

The overall general purpose is to improve blood sugar control by stabilizing glucose levels in adults. This is achieved through complementary physiological actions: the DPP-4 inhibitor supports post-meal glucose responses, while the biguanide reduces baseline glucose output.

Regulatory References

  1. Velmetia EPAR Product Information
  2. NIH MedlinePlus Drug Information for Metformin
  3. Metformin: MedlinePlus Drug Information
Advertisements

What side effects are possible with Велметия?

The official safety profile for Velmetia (Sitagliptin/Metformin) documents adverse reactions classified by frequency and affected organ system, based on clinical data and post-marketing reports from government regulatory agencies (e.g., FDA, EMA).

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common (ge 1/100 patients) Headache, Hypoglycaemia (when used with insulin or sulfonylureas), Gastrointestinal effects (Nausea, Diarrhea, Vomiting, Abdominal pain), and Upper Respiratory Tract Infection [FDA Label].
Rare (Post-marketing) Lactic Acidosis (a rare but serious metabolic complication of the Metformin component) [EMA SmPC].
Frequency Not Known Acute Pancreatitis, Severe and disabling Arthralgia, Hypersensitivity Reactions (Anaphylaxis, Angioedema), and Bullous Pemphigoid [FDA Label].

System-Organ Classes and Serious Reactions

The label documents effects across several systems, including Metabolism and Nutrition Disorders (Hypoglycaemia, Vitamin B12 deficiency), Gastrointestinal Disorders (Nausea, Vomiting, Acute Pancreatitis), Nervous System Disorders (Headache), and Skin and Immune System Disorders (Bullous Pemphigoid). The most critical adverse events listed are Lactic Acidosis and Acute Pancreatitis, which are classified as serious adverse reactions in regulatory sources.

Safety-Related Restrictions and Considerations

The regulatory profile defines use by specific patient conditions:

  • Contraindications: The medicine is strictly contraindicated in cases of severe renal impairment (eGFR < 30 mL/min/1.73 m^2) and conditions such as Type 1 Diabetes Mellitus or Diabetic Ketoacidosis [FDA Label].
  • Population Notes: Use is not recommended in patients with hepatic impairment. Due to the risk of Lactic Acidosis, older adults require more frequent assessment of renal function [EMA SmPC].
  • Exposure Patterns: Gastrointestinal side effects are often reported upon initiation of therapy, while monitoring of Vitamin B12 levels is advised for potential deficiency with long-term exposure [FDA Label].

The official safety information structures the understanding of risks by defining a range of expected, common effects and clearly separating them from rare but severe events which necessitate stringent population-specific restrictions, as determined by regulatory authorities.

Advertisements

Overdose and Emergency Response

The regulatory overdose profile for Велметия is critically defined by the severe, life-threatening risk of Metformin-associated Lactic Acidosis. This serious metabolic complication is associated with a high fatality rate, and official documentation mandates specific emergency actions.

Documented Manifestations Required Emergency Action
Onset is often subtle, including malaise, myalgias (muscle pain), somnolence, respiratory distress, and abdominal distress. Severe presentations include hypotension, hypothermia, and resistant bradyarrhythmias. Immediate medical attention is required upon suspicion of Lactic Acidosis. The product must be immediately discontinued and the patient hospitalized immediately for supportive care and monitoring.

Overdose is associated with laboratory findings of severe anion gap acidosis and elevated blood lactate levels. No specific antidote is available for this toxicity. Treatment is procedural: prompt hemodialysis is recommended for the correction of severe acidosis and the elimination of accumulated Metformin from the system. The risk of severe outcomes is officially noted to be significantly increased in populations with renal impairment, hepatic impairment, or advanced age 65 years or greater.

Advertisements

Therapeutic Uses of Велметия

The medicine is commonly used for the management of Type 2 Diabetes Mellitus, addressing symptoms related to systemic imbalance, specifically the chronic elevation of glucose. The medication is intended to support improved control of blood glucose levels in adults.

Velmetia is applied in clinical settings that involve acute or unstable symptom patterns when therapy needs intensification. It is relevant in three key scenarios: when Metformin monotherapy is insufficient, as part of triple combination therapy with a sulfonylurea or a PPAR-gamma agonist, or as an add-on to insulin therapy. The medication may assist with supporting functional stability, designed to address previous treatment limitations.

It is generally applied in situations where symptoms reflect a persistent glucose imbalance. This support generally helps ease the overall symptom burden and may assist the patient with achieving metabolic goals.

“This medication is commonly used to help with managing symptom clusters that may become intense or disruptive when single-agent treatments have reached their limit.”


Quick Fact: Relief for Chronic Hyperglycemia Velmetia plays a role in managing both high fasting and post-meal glucose readings, which contributes to the ultimate benefit of reducing elevated HbA1 c levels.

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Velmetia (sitagliptin/metformin) is authorized for use in adult patients with Type 2 Diabetes Mellitus. Eligibility is strictly defined by regulatory documents, which establish clear exclusions for certain populations and health conditions.

Populations Who Must Not Use Velmetia (Contraindicated)

  • Severe Renal Impairment: Patients with an estimated Glomerular Filtration Rate (eGFR) below 30 mL/min/1.73 m^2 are excluded due to the risk of metformin accumulation and lactic acidosis.
  • Metabolic Acidosis: Patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis or pre-coma.
  • Other Diabetes Types: Patients with Type 1 Diabetes Mellitus.
  • Hepatic Impairment: Patients with any clinical or laboratory evidence of hepatic disease.
  • Hypersensitivity: Individuals with a history of serious allergic reactions (e.g., anaphylaxis, angioedema) to the active ingredients or formulation components.
  • Breastfeeding Women and those with Acute Alcohol Intoxication.

Eligibility-Related Restrictions

  • Moderate Renal Impairment: Use is not recommended for initiation in patients with eGFR between 30 and 45 mL/min/1.73 m^2. Monitoring of renal function is necessary for all users, especially the elderly.
  • Age: Safety and efficacy have not been established for use in the pediatric population (under 18 years of age).
  • Pregnancy: Use is not recommended during pregnancy; alternative treatments should be considered.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Velmetia (Sitagliptin/Metformin) documents specific pharmacokinetic and pharmacodynamic interaction patterns. The combination with Iodinated Contrast Agents is classified as a temporarily contraindicated combination, requiring the product to be withheld prior to, or at the time of, the procedure. This mandatory timing separation is required because the risk of lactic acidosis due to Metformin accumulation is significantly heightened under conditions of transient renal compromise, particularly in patients with existing renal impairment.

Interaction Type Interacting Substance/Class Regulatory Outcome Statement
Transporter-Mediated Cimetidine, Ranolazine, Dolutegravir Increases Metformin plasma concentrations (AUC/Cmax) by inhibiting renal transporters (OCT2/MATE).
Transporter-Mediated Cyclosporine Increases Sitagliptin plasma concentrations by inhibiting the OAT3 transporter.
Pharmacodynamic Insulin or Sulfonylureas Additive effect, increasing the risk of hypoglycemia.
Pharmacodynamic Alcohol Increases the risk of lactic acidosis associated with the Metformin component.

Regulatory documents state that co-administration with other anti-hyperglycaemic agents necessitates caution due to the additive pharmacodynamic effect. Furthermore, strong inhibitors or inducers of CYP enzymes are not expected to cause clinically significant changes in the exposure of either Sitagliptin or Metformin.

Advertisements

Mechanism of Action

Dual-Action Enzyme Inhibition and Metabolic Modulation

The medication influences glucose regulation through two distinct, complementary mechanisms. One component acts as a selective inhibitor of the Dipeptidyl peptidase-4 (DPP-4) enzyme, an action that preserves the body's natural incretin hormones. The other component modulates metabolic pathways in the liver and peripheral tissues, primarily by activating the Adenosine Monophosphate-Activated Protein Kinase (AMPK) pathway to influence glucose production.


Enhancing Natural Glucose-Regulating Hormones

This mechanism focuses on the incretin axis, a hormonal signaling system. By blocking the DPP-4 enzyme, the active levels of GLP-1 and GIP are sustained. These preserved hormones signal the pancreas to enhance the release of insulin in a glucose-dependent manner and concurrently limit the release of glucagon, supporting a more regulated state of glucose concentration following nutrient ingestion.


Reducing Liver Glucose Output and Enhancing Tissue Use

This second core mechanism involves two key actions: it suppresses the liver's internal process of gluconeogenesis, thereby reducing the amount of endogenous glucose released into the bloodstream, and it enhances the ability of muscle and fat cells to take up and utilize circulating glucose. The resulting physiological effect is a reduction in basal circulating glucose concentrations and enhanced whole-body glucose disposal.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Велметия is a fixed-dose combination agent administered orally as a film-coated tablet. The tablet is designed to be swallowed whole and must not be split or crushed as part of the preparation requirements.


Dosing and Schedule

The medicine is typically taken twice daily (BID) and is required to be taken with meals to minimize gastrointestinal discomfort. Dosage is individualized based on the patient's existing regimen and tolerability. The dose may be adjusted up to the maximum daily limit of 100 mg Sitagliptin and 2,000 mg Metformin HCl. In the event of a missed dose, the protocol is to take it as soon as possible, unless it is almost time for the next dose, avoiding the use of a double dose.


Procedural and Population-Specific Use

Clinical protocols include specific limitations based on renal function. The medicine is contraindicated when the estimated Glomerular Filtration Rate (eGFR) is below 30 mL/min/1.73 m^2, and initiation of therapy is generally not recommended when eGFR is between 30-45 mL/min/1.73 m^2. Furthermore, Велметия may require temporary discontinuation at the time of or prior to diagnostic procedures involving iodinated contrast agents. Use is not established for pediatric patients.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Велметия

The clinical evidence for the combination of sitagliptin and metformin (Велметия) was evaluated in a range of studies, primarily Randomized Controlled Trials (RCTs). This overview describes the structure of that research, the outcomes monitored, and where limitations remain, using neutral language consistent with scientific uncertainty.


Evidence for Use as an Initial Dual Therapy (Add-on to Metformin)

Researchers conducted short- to mid-term Randomized Controlled Trials (RCTs) to research examined the combination in adults with Type 2 Diabetes Mellitus whose blood sugar levels were inadequately controlled with metformin alone. These trials involved administering the combination and observing its effect over defined time intervals, often around 18 to 24 weeks.

The main outcomes monitored in these core studies were changes in the biomarkers of systemic or functional imbalance, particularly Glycosylated Hemoglobin ( HbA1 c), as well as Fasting Plasma Glucose (FPG). Studies monitored the changes in the measured HbA1 c levels in the observed populations during the study period. Research contributes to the broader evidence landscape by describing patient patterns observed during the study.


Research on Intensified Regimens (Triple Therapy and Insulin Add-on)

Research was studied for use in patients whose condition presented with insufficient control on dual therapy. Studies monitored the combination as a third or fourth agent, such as when it was evaluated in existing treatment regimens involving metformin and a sulfonylurea or a similar agent. Furthermore, research examined the combination when added to a stable dose of insulin.


Study Landscape: Uncertainty and Research Gaps

Follow-up durations were typically limited in the primary research, often lasting between 18 and 54 weeks. However, long-term data from extension studies and real-world observational research describe patterns related to participants observed for periods up to two to four years in some cohorts.

Limited information for long-term outcomes is available for this combination, particularly concerning outcomes reflecting the prevention of major complications, such as cardiovascular events. Comparative evidence remains limited in some therapeutic scenarios. The research contributes to understanding symptom patterns, but findings were mixed in certain smaller, less standardized studies.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Велметия (FAQ)


Q: How quickly do people usually start feeling the effects of Велметия?

Studies monitoring the medicine typically measure the main blood sugar stabilizing effect over several weeks, looking at a key biomarker called Glycosylated Hemoglobin ( HbA1 c). However, the individual components reach their peak concentration in the bloodstream relatively quickly—in approximately one to four hours following administration. Regulatory documents indicate the medicine is intended for chronic management of the condition.


Q: What research evidence supports the use of Велметия?

According to official product information and clinical reviews, research, primarily consisting of Randomized Controlled Trials (RCTs), has examined the use of this combination medicine. These studies indicate that the medicine helps improve overall blood sugar control, often measured as a reduction in HbA1 c levels in adults with Type 2 Diabetes Mellitus.


Q: How does the mechanism of Велметия differ from traditional medicines for the same condition?

This medicine utilizes a dual approach to blood sugar control. One component belongs to the biguanide class, which is an older, established approach that reduces glucose output from the liver. The second component is from the newer DPP-4 inhibitor class, which works by boosting the body's natural hormones (incretins) to help the pancreas release insulin in response to food.


Q: Is it common for people to switch from another drug to Велметия?

Regulatory documents state that this medicine is commonly indicated for use when a patient's blood sugar is not adequately controlled on Metformin alone or in combination with other anti-hyperglycemic agents. Regulatory documents describe the medicine's role as part of an intensified treatment strategy.


Q: Can I use Велметия if I am already taking blood pressure medicine?

Official regulatory documents do not list all blood pressure medicines as a known contraindicated class. However, caution is advised when combining any medicines. Regulatory information advises disclosure of all current medications, allowing a healthcare professional to assess the potential for interactions.


Q: Does Велметия interact with common over-the-counter pain relievers?

While specific pain relievers are not always detailed in full in official drug interaction tables, certain non-steroidal anti-inflammatory drugs (NSAIDs) may affect kidney function. Caution is described in regulatory sources regarding co-administration of agents that may potentially compromise renal (kidney) function.


Q: What are the key things to mention to my doctor before starting Велметия?

Regulatory information specifies that disclosure is required for existing severe kidney or liver problems, Type 1 Diabetes, a history of metabolic acidosis, or any severe allergic reaction to the active components of the medicine. This information allows the healthcare professional to assess the patient's eligibility and potential risks, as required by regulatory guidelines.


Q: Can older adults typically use Велметия?

Official information indicates that use in older adults is generally permitted. However, due to the potential for age-related decline in kidney function, more frequent assessment and monitoring of renal function is specifically advised for this population, as the Metformin component is cleared by the kidneys.


Q: What should I do if I experience a mild stomach upset while taking Велметия?

Gastrointestinal effects, such as nausea and stomach pain, are commonly reported, especially when starting the medication. The official administration instructions require the tablet to be taken with meals, which is a regulatory strategy described to help minimize this type of digestive discomfort.


Q: Is Велметия commonly used for conditions other than what it is officially approved for?

The regulatory indication for this medicine, as defined by official governmental documents, is exclusively for the management of Type 2 Diabetes Mellitus. The medicine's use is limited to the conditions specified in its official regulatory indication.


Q: What is the difference between Велметия and [Drug X, a similar common drug]?

Official regulatory documents establish this medicine as a fixed-dose combination containing two active ingredients from two different pharmacological classes (a biguanide and a DPP-4 inhibitor). Other similar-sounding medicines may contain only one of these components or belong to entirely different drug classes, leading to different effects.


Q: Does Велметия cause people to feel tired or dizzy?

Official safety sections document effects on the Nervous System, such as headache. Additionally, if the medicine is taken with certain other anti-diabetes treatments, hypoglycemia (low blood sugar) can occur. Hypoglycemia is a condition that may cause symptoms such as dizziness or fatigue.


Q: Is it okay to drive a car while taking Велметия?

Official regulatory documents advise that patients should be aware of the potential risk of hypoglycemia (low blood sugar), which is possible when this medication is combined with a sulfonylurea or insulin. Hypoglycemia can potentially affect the ability to safely drive or operate heavy machinery.


Q: Is Велметия known to cause weight changes?

Regulatory adverse reaction profiles document clinical observations related to weight in studies. The specific findings regarding weight-related outcomes documented in clinical trials can be found in the prescribing information.


Q: Why do some people say Велметия gave them headaches?

Headache is documented in official regulatory sources as a commonly reported adverse reaction. This finding is based on data collected from clinical trials and ongoing post-marketing surveillance of the medicine.


Q: Is it normal to feel a change in appetite while on Велметия?

Official adverse reaction profiles document general gastrointestinal effects such as nausea and abdominal pain. A change in appetite is not always explicitly specified but may be an associated response to these commonly reported digestive effects.


Q: Is Велметия known to be habit-forming?

This medicine is not classified as a controlled substance by regulatory authorities.


Q: What is the shelf life of Велметия?

Regulatory labeling provides the required temperature range and container protection instructions for storage to maintain the product’s stability and potency. The specific expiration date is printed on the packaging.


Q: Are there different forms of Велметия (e.g., liquid, tablet)?

Official regulatory labeling defines the product as a fixed-dose, film-coated tablet for oral use. Other physical forms, such as a liquid or a capsule, are not typically specified in the regulatory packaging information.


Q: Is Велметия ever used as a short-term treatment?

The medicine is indicated for the chronic management of Type 2 Diabetes Mellitus, implying a long-term treatment strategy. While clinical trials may have limited duration, the overall goal of the medicine is sustained blood sugar control.


Q: Why is Велметия sometimes given with another medicine?

The medicine is indicated for use in combination with a variety of other anti-hyperglycemic agents, such as a sulfonylurea or insulin. This approach is taken when blood sugar is not adequately controlled by fewer medicines alone, allowing multiple pathways related to the condition to be addressed simultaneously.


Q: Is Велметия affected by grapefruit or grapefruit juice?

Official regulatory documents and drug labels do not commonly identify grapefruit or grapefruit juice as having a known or specific interaction with the active components of this medicine.


Q: Can I take Велметия if I have diabetes?

This medicine is specifically indicated for adults with Type 2 Diabetes Mellitus. However, regulatory contraindications strictly prohibit its use in patients diagnosed with Type 1 Diabetes Mellitus or diabetic ketoacidosis.


Q: Does Велметия affect liver function?

Regulatory documents state that the medicine is strictly contraindicated in patients with clinical or laboratory evidence of existing hepatic (liver) impairment. The medicine should not be used in these populations.


Q: How is the safety profile of Велметия generally described in studies?

The safety profile is established by documenting adverse events in clinical trials and post-marketing reports. This documentation describes a known profile of common side effects, such as headache or gastrointestinal issues, and separates them from rare but severe events like lactic acidosis.


Q: Is it normal to feel nervous when first starting Велметия?

Official adverse event sections document nervous system disorders in regulatory documents. While 'nervousness' may not be an explicitly listed common effect, similar psychological and neurological effects are noted in the official safety monitoring reports.


Q: How does Велметия compare to older medicines used for the same issue?

Regulatory documents state that one component (Metformin) belongs to the biguanide class, which has a long history of use, and the other (Sitagliptin) is a newer DPP-4 inhibitor. The combination strategy allows for a comprehensive approach that targets multiple physiological factors involved in Type 2 Diabetes.

Advertisements

How should Велметия be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for Velmetia (Sitagliptin/Metformin) are based on regulatory labeling to maintain product stability and ensure public safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C.
Protection Keep the medicine in its original container to protect it from moisture. Packaging may include a desiccant.
Safety The product is supplied with a child-resistant closure. Keep Velmetia out of the reach of children.

Disposal Instructions

Official disposal rules require unused or expired medicine to be discarded safely. The product should not be disposed of in household trash or flushed down the toilet. Follow local regulations or return the product to a pharmacy take-back program to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Велметия found in:

A-Z Index: